FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?†-Reference-Cited by-同舟云学术

FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?†

Published:2020-11 Issue:5 Volume:78 Page:682-687
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

van Rhijn Bas W.G.,Mertens Laura S.,Mayr Roman,Bostrom Peter J.,Real Francisco X.,Zwarthoff Ellen C.,Boormans Joost L.,Abas Cheno,van Leenders Geert J.L.H.,Götz Stefanie,Hippe Katrin,Bertz Simone,Neuzillet Yann^ORCID,Sanders Joyce,Broeks Annegien,van der Heijden Michiel S.,Jewett Michael A.S.,Marquez Mirari,Stoehr Robert,Zlotta Alexandre R.,Eckstein Markus,Soorojebally Yanish,Roshani Hossain,Burger Maximilian,Otto Wolfgang,Radvanyi François,Sirab Nanor,Pouessel Damien,Wullich Bernd,van der Kwast Theo H.,Malats Núria,Hartmann Arndt,Allory Yves,Zuiverloon Tahlita C.M.

Funder

University of Toronto

Dutch Cancer Society

European Urological Scholarship program

French Urological Association

Publisher

Elsevier BV

Subject

Urology

Reference10 articles.

1. Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer;Alfred Witjes;Eur Urol,2017

2. Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study;Necchi;J Clin Oncol,2018